SITE004-0041

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE004 (DEU) · Dr. Tanaka
consented 2022-04-06

AEs

Serious

Dropout signal

–

Adverse events

mild assessed

Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-05-30 (study day 34); relationship: N

moderate assessed

Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-05-30 (study day 34); relationship: Y

moderate assessed

Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-12-17 (study day 235); relationship: not assessed

mild assessed

Grade 1 Alopecia — outcome: UNKNOWN; onset 2023-01-18 (study day 267); relationship: not assessed

severe serious assessed

Grade 3 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-04-28 (study day 367); relationship: N; serious criteria: hospitalization

Data queries

No data queries.